


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-2.17%
+6.81%
+2.00%
-7.29%
-26.16%
PVLA
Palvella Therapeutics Inc
$93.00
Strengths

Upgraded on attractively valued
Chart
$75.66 (+22.92%)
$56.45 (+64.75%)
$56.45 (+64.75%)
$56.45 (+64.75%)
PVLA has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Low volume

PVLA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
![]()
PVLA Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
PVLA Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is PVLA current stock price?
What are PVLA stock strengths?
What is PVLA Risk Level?
What is PVLA market cap and volume?
What is PVLA current Stock IQ?
Should I buy PVLA stock right now?
Is PVLA a Strong Buy right now?
What does a 'Strong Buy' rating mean for PVLA?
What does a 'Strong Sell' rating mean for PVLA?
What factors influence PVLA's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.17%
+6.81%
+2.00%
-7.29%
-26.16%
PVLA
Palvella Therapeutics Inc
Current Price
$93.00
Stock Insights
Strengths

Upgraded on attractively valued

Chart
$75.66 (+22.92%)
$56.45 (+64.75%)
$56.45 (+64.75%)
$56.45 (+64.75%)
PVLA Analysts Opinion
PVLA Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
![]()
PVLA Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
PVLA Street Sentiment is extremely bullish and have positive views on the near-term outlook
PVLA has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Low volume

Average key support and resistance price levels.
PVLA Latest Analysis
Raymond James Upgrades Palvella Therapeutics (PVLA). Fintel reports that on November 19 2025 Raymond James upgraded their outlook for Palvella Therapeutics (NasdaqCM:PVLA) from Outperform to Strong Buy. Analyst Price Forecast Suggests 19.23% Upside
Today
Palvella Therapeutics (PVLA) Price Target Increased by 39.58% to 115.65. The average one-year price target for Palvella Therapeutics (NasdaqCM:PVLA) has been revised to $115.65 / share. This is an increase of 39.58% from the prior estimate of $82.85 dated November 7 2025. The price target is an average of many targets provided by
Mon Nov 17, 2025
Canaccord Genuity Maintains Palvella Therapeutics (PVLA) Buy Recommendation. Fintel reports that on November 13 2025 Canaccord Genuity maintained coverage of Palvella Therapeutics (NasdaqCM:PVLA) with a Buy recommendation. Analyst Price Forecast Suggests 2.92% Upside
Fri Nov 14, 2025
Chardan Capital Maintains Palvella Therapeutics (PVLA) Buy Recommendation. Fintel reports that on November 7 2025 Chardan Capital maintained coverage of Palvella Therapeutics (NasdaqCM:PVLA) with a Buy recommendation. Analyst Price Forecast Suggests 5.37% Upside
Fri Nov 7, 2025
HC Wainwright & Co. Maintains Palvella Therapeutics (PVLA) Buy Recommendation. Fintel reports that on November 6 2025 HC Wainwright &. Co. maintained coverage of Palvella Therapeutics (NasdaqCM:PVLA) with a Buy recommendation. Analyst Price Forecast Suggests 9.38% Upside
Thu Nov 6, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
PVLA Stock trends
PVLA Stock performance
PVLA Stock analysis
PVLA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.